The Increasing Transparency in Generic Drug Applications Act amends the federal framework governing abbreviated new drug applications (ANDAs) by adding a new provision to require disclosures when determining if a drug is qualitatively and quantitatively the same as the listed drug. The bill also directs the Department of Health and Human Services to issue draft guidance within one year describing how sameness is assessed, including considerations around pH adjusters.
The applicability of the new rules begins on enactment. The goal is to make the basis for BE determinations more transparent, reduce ambiguity in what constitutes sameness, and provide stakeholders with a clearer view of when and why certain differences are deemed acceptable or not.
At a Glance
What It Does
The bill adds a new subsection to 505(j)(3) requiring disclosures about BE determinations for abbreviated generics. If a drug is not qualitatively or quantitatively the same as the listed drug, the FDA must identify the ingredient(s) causing the difference and disclose the magnitude of any deviation. If it is the same, the agency can still revise a determination only under specified conditions.
Who It Affects
ANDA applicants, FDA reviewers, and listed drug sponsors; healthcare providers and patients will benefit from clearer BE criteria and disclosure.
Why It Matters
It creates a formal, auditable trail for sameness decisions, reduces uncertainty for manufacturers, and potentially improves safety and market competition by clarifying the data behind BE determinations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill expands how the FDA handles bioequivalence determinations for abbreviated GENERIC drug applications. It adds a new requirement that, when an abbreviated application is reviewed to decide if a drug is the same as the listed product, the agency must disclose whether the drug is qualitatively and quantitatively the same and, if not, reveal which inactive ingredients caused the difference and how large that difference is.
The law also requires the agency to provide a path for cases where sameness is confirmed, including conditions under which a prior determination could be revised. These disclosures are meant to be lawful and do not undermine protections for confidential information.
In addition, the bill directs the Department of Health and Human Services to issue draft guidance within one year describing how sameness will be determined, with a public comment period and a final guidance within another year after the comment period closes. The provisions apply upon enactment.
Overall, the bill aims to standardize transparency around BE determinations to help manufacturers, reviewers, and stakeholders understand when generics truly match listed products and why any deviations are allowed or not.
The Five Things You Need to Know
The bill adds 505(j)(3)(H) to require BE disclosures for abbreviated generics.
If not the same, the FDA must identify ingredients causing the difference and quantify the deviation.
If the same, a prior determination can only be revised under limited circumstances.
Disclosures are lawful and do not automatically expose nonpublic information.
HHS must issue draft guidance within 1 year and final guidance within another year.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Disclosures on sameness determinations
This subsection adds the requirement that when an abbreviated generic drug is reviewed, the Secretary must inform whether the drug is qualitatively and quantitatively the same as the listed drug. If not, the agency must disclose which ingredient(s) cause the difference and the quantitative deviation. This enhances transparency around the basis for BE determinations and the data behind them.
Guidance on sameness determinations
The Secretary must issue or update draft guidance within one year of enactment describing how sameness is determined, including assessment of pH adjusters. The process requires a draft, a minimum 60-day public comment window, and final guidance within one year after the close of comments, ensuring a transparent, iterative rulemaking approach.
Applicability and timing
The new BE disclosure framework applies on the date of enactment, regardless of when the accompanying guidance is finalized. This ensures immediate impact on current and future ANDA reviews and alignment with the new transparency expectations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- ANDA applicants gain clearer visibility into the BE basis and required data for demonstrating sameness
- FDA reviewers gain a structured, auditable framework for BE determinations
- Listed drug sponsors benefit from standardized disclosures that clarify competition landscapes
- Healthcare payers and providers gain insight into BE decisions that influence coverage and pricing
- Patients ultimately benefit from more transparent information about generic drug equivalence
Who Bears the Cost
- ANDA sponsors bear potential additional data preparation costs and timelines to explain deviations
- FDA reviewers face increased workload to assess and document disclosures
- Listed drug sponsors incur scrutiny on ingredient-level disclosures that may affect competitive positioning
- Small manufacturers may incur compliance costs associated with enhanced transparency
- Payers may experience shifts in pricing or formularies as BE determinations become more explicit
Key Issues
The Core Tension
The central dilemma is whether increased disclosure improves patient safety and market competition without inadvertently exposing sensitive competitive information or creating bottlenecks in generic approvals. The bill resolves this by limiting disclosures to information explicitly permitted by law and by tying potential revisions of sameness determinations to specific, narrowly defined changes or identified errors.
The bill’s transparency provisions hinge on how much information is disclosed and how it is protected. While the disclosures authorized under the new subsections are lawful, they are not meant to reveal nonpublic qualitative or quantitative information about the ingredients in a listed drug beyond what the law permits.
The central tension is balancing public access to BE rationales with safeguards for confidential commercial information. The guidance process also raises questions about how consistent the determinations will be across reviewers and whether the added data will meaningfully affect generic competition or simply add complexity to filings.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.